Background
Terumo Blood and Cell Technologies is aware of and is currently monitoring AMNESIA:33.
As a result, product technical teams are performing technical assessments to determine if AMNESIA:33 presents a measurable cybersecurity risk.
Response
Terumo Blood and Cell Technologies is currently working with each product team and assessing if and how AMNESIA:33 could be used to exploit our products. While some technical assessments have been completed, others are still ongoing.
Terumo Blood and Cell Technologies products that are confirmed to be unaffected by AMNESIA:33 –
The product list below is available to customers to help identify existing Terumo Blood and Cell Technologies products that have been confirmed to be unaffected by AMNESIA:33. The list provided below is not comprehensive and may be updated as more products are assessed. It does not indicate the patch or device status.
- Reveos® Automated Blood Processing System
- FINIA® Fill and Finish System
- Cell Processing Application
- Trima Accel® Procedure Summary
- Vista® Information System
- Trima Accel® Automated Blood Collection System
- Quantum® Cell Expansion System
- Cadence® Data Collection System
- Spectra Optia® Apheresis System
- Mirasol® Pathogen Reduction Technology
- InfoVu
- Trima KPI Dashboard
- TOMEs - Terumo Operational Medical Equipment Software
- T-RAC II - Terumo Recording & Automatic Blood Collector
- T-ACE II+ - Terumo Automatic Component Extractor
- Trucise® Data Management System
Customers that maintain patches independent of Terumo Blood and Cell Technologies delivery should ensure these actions are performed as the acting responsible entity in order to maintain the correct security posture of the system(s).